Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2206

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2206
---
 PfGARP/PfSEA License Agreement (RIH #154): the filing of an IND within two years after commencing IND-enabling studies; the completion
    of a Phase 1/2 clinical trial within one and a half years following the filing of an IND; and the completion of a Phase 3 clinical
    trial within three years following completion of a Phase 1/2 clinical trial.

    ●
    The
    Brown Anti-PfGARP Small Molecules License Agreement (BROWN ID 3085J): the filing of an IND in 2027; the commencement of Phase 1/2
    clinical trials in 2027; and the commencement of a Phase 3 clinical trial in 2029.

92

A
core element of our business strategy also includes continuing to acquire or in-license additional technologies or product candidates.
As a result, we intend to periodically explore a variety of possible strategic collaborations or licenses in an effort to gain access
to additional product candidates, technologies or resources.

Furthermore,
license agreements we enter into in the future may not provide exclusive rights to use intellectual property and technology in all relevant
fields of use and in all territories in which we may wish to develop or commercialize our technology and products. As a result, we may
not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses.

Collaborations
are and will be important to our business. If we are unable to enter into new collaborations, or if these collaborations are not successful,
our business could be adversely affected.

A
part of our strategy is to maximize the value of our product candidates by evaluating partnerships where we believe partners can add
significant commercial and/or development capabilities. Further, we have limited capabilities for product development and do not yet
have any capability for commercialization. Accordingly, we have and may in the future enter into collaborations with other organizations
to provide us with important technologies and funding for our programs and technology.

The
collaborations we enter into may pose a number of risks, including the following:

    ●
    collaborators
    have significant discretion in determining the efforts and resources that they will apply;

    ●
    collaborators
    may not perform their obligations as expected;

    ●
    collaborators
    may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue
    or renew development or commercialization programs or license arrangements based on clinical trial results, changes in the collaborators’